<DOC>
	<DOCNO>NCT02631070</DOCNO>
	<brief_summary>The study conduct compliance International Council Harmonisation ( ICH ) Technical Requirements Registration Pharmaceuticals Human Use/Good Clinical Practice ( GCP ) applicable regulatory requirement . This Phase 3 , double-blind , randomize , placebo-controlled , multicenter study determine efficacy safety luspatercept ( ACE-536 ) versus placebo subject anemia due International Prognostic Scoring System-Revised ( IPSS-R ) low , low , intermediate Myelodysplastic syndrome ( MDS ) ring sideroblast ( ≥ 15 % ) require Red blood cell ( RBC ) transfusion .</brief_summary>
	<brief_title>A Study Luspatercept ( ACE-536 ) Treat Anemia Due Very Low , Low , Intermediate Risk Myelodysplastic Syndromes</brief_title>
	<detailed_description>Anemia consider one prevalent cytopenia patient myelodysplastic syndrome , umbrella term use describe disorder relate ineffective production red blood cell , white blood cell , and/or platelet . Ranging severity mild ( asymptomatic ) severe , anemia result patient require regular red blood cell ( RBC ) transfusion , lead complication iron overload . The goal study assess safety efficacy luspatercept versus placebo anemic patient categorize International Prognostic Scoring System-Revised ( IPSS-R ) low , low , intermediate risk Myelodysplastic syndrome ( MDS ) , ring sideroblast present , require constant RBC transfusion . The design study allow period initial randomization patient either luspatercept placebo arm , follow double-blind treatment period , MDS disease assessment visit . For patient determine experience clinical benefit judge study Investigator disease assessment visit , permit enter double-blind Extension Phase study . Once patient discontinue study treatment , enter post treatment follow-up period .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study : 1 . Subject ≥ 18 year age time sign informed consent form ( ICF ) . 2 . Subject diagnosis Myelodysplastic syndrome ( MDS ) ( accord WHO 2008 ) meet International Prognostic Scoring SystemRevised ( IPSSR ) classification low , low , intermediate risk disease Ring sideroblasts ≥ 15 % erythroid precursor bone marrow Fewer 5 % blast bone marrow 3 . Subjects require red blood cell transfusion ≥ 2 unit 8week period 4 . Eastern Cooperative Oncology Group ( ECOG ) score 0 , 1 , 2 5 . Subjects refractory/intolerant/ineligible prior ESA treatment , define : Refractory prior Erythropoiesis stimulating agent ( ESA ) treatment : documentation nonresponse response longer maintain prior ESAcontaining regimen , either single agent combination ( eg , GCSF ) ; ESA regimen must either recombinant human erythropoietin ( rHu EPO ) ≥ 40,000 IU/wk least 8 dos equivalent OR darbepoetin alpha ≥ 500 μg Q3W least 4 dos equivalent Intolerant prior ESA treatment : documentation discontinuation prior ESAcontaining regimen , either single agent combination ( eg , GCSF ) , time introduction due intolerance adverse event ESA ineligible : low chance response ESA base endogenous serum erythropoietin level &gt; 200 U/L subject previously treat ESAs The presence follow exclude subject enrollment : 1 . Prior therapy disease modify agent ( eg , immunemodulatory drug [ IMiDs lenalidomide ] , hypomethylating agent , immunosuppressive therapy [ IST ] ) experimental agent underlie Myelodysplastic syndrome ( MDS ) disease 2 . Previously treat either luspatercept ( ACE536 ) sotatercept ( ACE011 ) 3 . MDS associate del 5q cytogenetic abnormality 4 . Secondary MDS , ie , MDS know arisen result chemical injury treatment chemotherapy and/or radiation disease . 5 . Known clinically significant anemia due iron , vitamin B12 , folate deficiency , autoimmune hereditary hemolytic anemia , gastrointestinal bleeding iron deficiency determine bone marrow aspirate stain iron , calculate transferrin saturation ( iron/total iron bind capacity ) ≤ 20 % , serum ferritin ≤ 15 μg/L 6 . Prior allogeneic autologous stem cell transplant 7 . Known history diagnosis Acute myeloid leukemia ( AML ) 8 . Use follow within 5 week prior randomization : anticancer cytotoxic chemotherapeutic agent treatment corticosteroid , except subject stable decrease dose ≥ 1 week prior randomization medical condition MDS ironchelating agent , except subject stable decrease dose least 8 week prior randomization red blood cell ( RBC ) hematopoietic growth factor ( eg , Interleukin3 ) 15 . Prior history malignancy , MDS , unless subject free disease ≥ 5 year . However , subject follow history/concurrent condition allow : Basal squamous cell carcinoma skin Carcinoma situ cervix Carcinoma situ breast Incidental histologic find prostate cancer ( T1a T1b use tumor , node , metastasis [ TNM ] clinical staging system ) 16 . Major surgery within 8 week prior randomization . Subjects must completely recover previous surgery prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Luspatercept</keyword>
	<keyword>Transfusion dependent</keyword>
	<keyword>Lower risk</keyword>
	<keyword>Low risk</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>ESA refractory</keyword>
	<keyword>ESA intolerant</keyword>
	<keyword>ESA ineligible</keyword>
	<keyword>ACE-536</keyword>
	<keyword>Anemia</keyword>
	<keyword>Ring Sideroblasts</keyword>
	<keyword>Require Red Blood Cell Transfusions</keyword>
	<keyword>MEDALIST</keyword>
	<keyword>MDS</keyword>
	<keyword>IPSS-R low/IPSS-R low/IPSS-R intermediate</keyword>
</DOC>